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Clinics 
Age and sex: 32 years old male patient. 
Age and sex : 32 year(s) old male patient.  
Previous History : preleukemia (RAEB diagnosed in 
09-2006); Hodgkin's lymphoma diagnosed in 2003. 
Organomegaly : no hepatomegaly ; no splenomegaly ; 
enlarged lymph nodes (History of Hodgkin's lymphoma 
involving right side neck lymph node) ; no central 
nervous system involvement. 
Blood 
WBC: 0.29 x 109/l; Hb: 10.7 g/dl; platelets: 19x 109/l. 
Bone marrow: Megakaryocytes: none noted; Blasts: 
65%; Promyelocytes: 1%; Myeloid Activity: 20%, 
occasional dysplastic forms; Erythroid Activity: 12%, 
occasional dysplastic forms; Lymphocytes: 2%. 
Cytopathology classification 
Cytology: M2 arising from previous myelodysplastic 
syndrome (RAEB-1). 
Immunophenotype: Population of immature cells is 
positive for CD34 +, CD45 (dim), HLA-DR +, CD117 
+, CD13 +, and CD33+ and negative for CD15-, 
monocytic, B and T lymphoid markers. 
Pathology: Involvement by acute myelogenous 




Date of diagnosis: Hodgkin's lymphoma: (2003);  
myelodysplastic syndrome: (09-2006) karyotype was 
not performed; therapy-related AML: (01-11-2007) 
karyotype showing t(16;21) 
Treatment: Chemotherapy and radiotherapy; 
chlorambucil, Vinblastine Procarbazine, Prednisone 
(MOPP) until June 2004; radiotherapy in 2004; 
ifosfamide, carboplatin and etoposide (ICE) in August 
2005; autologous bone marrow transplant in August 
2006, and conditioning regimen consisted of Cytoxan, 
BCNU and etoposide. Induction therapy in January 
2007 (16-01-07) and preparation for second transplat. 
Complete remission was obtained  
Comments : bone marrow biopsy performed on 03-01-
2007 showing no evidence of leukemia and 2% of 
blast. Karyotype performed on bone marrow aspirate 
was interpreted as 46, XY in 20 metaphases. 
Relapse: - 
Status: Alive 03-2007 
Karyotype 




Other molecular cytogenetic technics: FISH evaluation 
for AML1 rearrangement was performed on abnormal 
metaphases with the LSI TEL/AML1 ES Dual Color 
Translocation Probe (Abbott Molecular/Vysis, Inc.). 
Other molecular cytogenetics results: Ish 
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Comments 
The t(16;21) was reported mostly in t-MDS/t-AML, 
and classified as M2 in a majority of cases. Two cases 
including this current report were observed after  
treatment for Hodgkin lymphoma. 
Trisomy 8 is a frequent secondary abnormality 
associated with t(16;21), however in this current case 
we also report the presence of an additional 






Partial GTG-banding karyotype showing t(16;21)(q24;q22)(a) and numerical anomalies. 
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